Intraductal Papillary Mucinous Neoplasm (IPMN) Database - A Tool to Predict Pancreatic Cancer

Launched by ST VINCENT'S HOSPITAL MELBOURNE · Nov 2, 2021

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how a specific type of pancreatic condition called Intraductal Papillary Mucinous Neoplasm (IPMN) can progress to pancreatic cancer. The goal is to gather important information that can help doctors predict which patients with IPMN are at higher risk of developing cancer, ultimately leading to earlier detection and better treatment options. Researchers will look at various factors, including medical imaging and biopsy results, to track the progression of IPMN and validate existing guidelines for managing this condition.

To participate in the trial, adults aged 18 to 90 who have been diagnosed with a cystic mass in the pancreas that is consistent with IPMN are welcome to join. Participants will undergo monitoring and may have additional tests, like endoscopic ultrasounds, to help assess their condition. This study is crucial because it aims to improve how we manage IPMN and could potentially save lives by catching pancreatic cancer earlier. If you are interested in learning more or think you might qualify, please reach out for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients between the age of 18 and 90 years old who have been identified with a cystic mass consistent with IPMN on imaging
• Exclusion Criteria:
• • Patients who formally decline enrolment into the study